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Abstract
Background: The identification of new prognostic markers for prostate cancer is highly warranted, since it is difficult to
identify patients requiring curative treatment. Data from both experimental models and clinical samples have identified
important functions of PDGFRb on pericytes and fibroblasts in the tumor stroma.
Methodology/Principal Findings: In this study the prognostic significance of PDGFRb in prostate cancer stroma, and in
matched non-malignant tissue, was evaluated with immunohistochemistry. PDGFRb expression was analyzed in normal and
tumor stroma from more than 300 prostate cancer patients. High PDGFRb expression in tumor stroma was associated with
large tumor size, advanced stage, high Gleason score and high vessel density. Perivascular PDGFRb staining in tumors was
also correlated with high Gleason score. Correlations were also observed between PDGFRb status in tumor stroma and non-
malignant stroma. Similarly, high PDGFRb expression in adjacent non-malignant tissue stroma correlated with large tumor
size, advanced stage, high Gleason score and proliferation in non-malignant epithelium. Interestingly, high levels of PDGFRb
in the stroma of tumor and non-malignant tissue were associated with shorter cancer specific survival in prostate cancer
patients.
Conclusions/Significance: The study revealed a number of novel associations between stromal PDGFRb expression in
prostate tumors and several important clinical characteristics, including survival.
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Introduction
Tumor behavior is, in general, largely governed by character-
istics of the tumor stroma. In the case of prostate cancer this is well
illustrated by a series of recent studies that have identified stromal
characteristics and markers with prognostic and response-predi-
cative significance.
Tumors with the most pronounced alteration in stroma
morphology, characterized by a major loss of smooth muscle cells
and increases in fibroblasts, myofibroblasts, and collagen fibres
(reactive stroma grade 3), have a poor outcome compared to those
with a stroma morphologically more similar to that in normal
prostate tissue, i.e. reactive stroma grades 1 and 2 [1]. Recent
studies have also shown that prostate cancers are characterized by
loss of androgen receptors (AR) in the stroma [2]. A low frequency
of stromal AR was coupled to increased Gleason score, metastasis,
poor response to castration therapy and an unfavorable outcome.
Furthermore, stromal characteristics, such as angiogenesis,
accumulation of macrophages, lymphocytes and mast cells as well
as changes in the extracellular matrix have been linked to
variations in prostate tumor behaviour [3,4,5,6,7]. Notably, it has
also been observed that cancer field effects and/or adaptive
changes may change the stroma and glandular epithelium in the
surrounding non-malignant tissue in a prognostically significant
manner [2,8,9,10].
PDGF a- and b-tyrosine kinase receptors exert important
control functions in mesenchymal cells, such as pericytes,
fibroblasts and vascular smooth muscle cells during development
[11,12]. Experimental studies have identified different functional
effects of stromal PDGF receptor signaling in various tumor
models. It has been demonstrated that paracrine activation of
PDGF receptors on fibroblasts acts as a potent signal for tumor
stroma recruitment [13,14,15]. Other studies have demonstrated
therapeutic benefits of targeting stromal PDGF receptors involving
either direct anti-tumoral effects, as well as beneficial effects on
tumor drug uptake [16,17,18,19,20]. Clinical significance of the
findings from experimental models is indicated by numerous
studies demonstrating stromal PDGF receptor expression in
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have been supplemented with analyses revealing that high stromal
PDGF receptor expression is a marker of an unfavorable outcome
in breast cancer patients [21].
The biological effects of PDGF receptors in tumor fibroblasts
and pericytes together with the advent of drugs with PDGF
receptor-inhibitory activity, such as imatinib, sorafenib and
sunitinib, thus motivates a systemic characterization of the
expression pattern of PDGF receptors in human solid tumors.
To this end, this study describes the expression of PDGFRb in
approximately 300 cases of prostate cancer and in matched
surrounding non-malignant prostate tissue, and also reports on
associations between PDGFRb expression and molecular, histo-
pathological and clinical characteristics.
Results
Variable PDGFRb expression in normal and tumor
prostate tissue
In order to evaluate the significance of PDGFRb in prostate
cancer, a TMA containing matched non-malignant and tumor
tissue from 377 prostate cancer patients with up to 25 year of
follow- up was analyzed by PDGFRb immunohistochemistry.
In agreement with previous studies, PDGFRb expression was
predominantly found in the fibromuscular stroma and in
perivascular cells (Figure 1 and Table 1). In the non-malignant
prostate 27% and 18% were scored as having positive PDGFRb
expression in the fibromuscular stroma and perivascular cells,
respectively. Perivascular and stroma staining were not correlated.
In the tumor areas 34% were positive in the fibroblast-like stroma
and 17% in the perivascular cells. Staining in tumor stroma and
around tumor blood vessels were correlated (Rs=0.59). Significant
associations were also observed between the PDGFRb status in the
malignant and non-malignant stroma (Table 1).
In some cases, the PDGFRb expression also varied within the
prostate tissue of the same patient (Figure S1).
Stromal PDGFRb expression occur predominantly in
aSMA-positive cells
To further characterize the stromal PDGFRb expression, a
double staining was performed with antibodies against aSMA and
PDGFRb.
These analyses confirmed that the majority of the PDGFRb
expression in the non-malignant fibromusclar and the fibroblast-
like tumor stroma occurred in aSMA-positive cells (Figure 2).
Furthermore, the analyses also demonstrated the presence
Figure 1. PDGFRb expression varies between prostate cancer patients in non-malignant and tumor tissue. Sections stained for the
PDGFRb from non-malignant (A, B and C) and tumor (D, E and F) tissue from prostate cancer patients. Cases A and D show negative staining, B and E
show moderate stromal staining whereas C and F present a strong stromal staining. Scale bar=200 mM.
doi:10.1371/journal.pone.0010747.g001
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malignant tissues which did not show any stromal PDGFRb
expression.
These findings thus confirm the existence of subsets of stromal
aSMA-positive cells, which differ with regard to PDGFRb expression.
Stromal and perivascular PDGFRb staining in prostate
tumors is correlated with prognostic markers
Analyses were performed to investigate possible associations
between PDGFRb expression in tumors and clinical parameters or
histological characteristics of the tumors.
Table 1. Bivariate correlations.
Non-malignant stroma PDGFRb IR Tumor stroma PDGFRb IR
Tumor stroma PDGFRb IR
1 r
n
0.32**
266
Non-malignant stroma PDGFRb IR
1 0.32**
266
Gleason score
{ r
n
0.15**
355
0.26**
287
Local tumor stage
{ r
n
0.11*
349
0.23**
282
Tumor size
1 r
n
0.16**
355
0.14*
287
Tumor cell proliferation
1
(Ki-67 labeling index)
r
n
0
342
0.03
282
Non-malignant epithelial cell proliferation
1
(K-i67 labeling index)
r
n
0.22**
348
0.12
272
Tumor vascular density
1
(vWf stained vessels)
r
n
0.10
145
0.28**
159
Non-malignant vascular density
1
(vWf stained vessels)
r
n
20.03
144
0.02
151
Notes:
1Pearson’s correlation test and
{Spearman’s correlation test. Data used in the correlation analysis were collected at the time of prostate cancer diagnosis.
*Correlation is significant at the ,0.05 level (2-tailed).
**Correlation is significant at the ,0.005 level (2-tailed).
Abbreviations: IR, immunoreactivity.
doi:10.1371/journal.pone.0010747.t001
Figure 2. PDGFRb is mainly expressed in aSMA-positive cells. Double stainings of prostate tissue with PDGFRb (green) and aSMA (red) in non-
malignant tissue (A and B) and tumor tissue (C and D). Scale bar=100 mM.
doi:10.1371/journal.pone.0010747.g002
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stroma was significantly positively correlated with large tumor size,
advanced stage, high Gleason score and high vessel density
(Table 1). In patients with a Gleason score 4–6 or Gleason score 7
tumor, only about 20% of the tumors showed stroma PDGFRb
staining, but it was considerably more common in cases with
Gleason score 8–10 tumors (Figure 3 A).
Perivascular PDGFRb expression in the tumor area was also
positively correlated with advanced stage, tumor vessel density and
high Gleason score (data not shown).
Together these findings demonstrate previously un-recognized
associations between stromal and perivascular PDGFRb expres-
sion in prostate tumors and characteristics associated with a more
aggressive cancer phenotype.
Stromal PDGFRb staining in the adjacent non-malignant
tissue are correlated with prognostic markers
PDGFRb expression in adjacent non-malignant tissue was also
analyzed with regard to associations with tumor characteristics
(Table 1).
High PDGFRb in non-malignant, fibromuscular stroma was
correlated with large tumor size, advanced stage, epithelial cell
proliferation and high Gleason score (Table 1). It was considerably
more common to find PDGFRb expression in the normal prostate
tissue stroma when a Gleason score 8–10 tumor was present
elsewhere in the organ compared to if the tumor was Gleason
score 4–6 (Figure 3 B).
Perivascular PDGFRb expression in the surrounding non-
malignant tissue was also positively correlated with epithelial cell
proliferation (data not shown).
These analyses thus suggest novel relationships between prostate
cancer properties and the phenotype of the stroma of the non-
malignant prostate tissue adjacent to prostate tumors.
Stromal PDGFRb expression in tumors and in the non-
malignant prostate tissue surrounding tumors predicts
cancer specific survival
The results from the analyses of PDGFRb expression were
finally combined with survival data to investigate possible
prognostic significance.
The cut-offs for tumor stromal PDGFRb and non-malignant
stromal PDGFRb in the analyses was set to the third quartile,
corresponding to 1.0 and 0.5 for tumour and non-malignant
stromal PDGFRb staining, i.e. high PDGFRb immunoreactivity
was $1.0 for tumour and $0.5 for non-malignant stroma.
Kaplan-Meier analysis showed that the watchful waiting
patients with the highest quartile of PDGFRb expression in tumor
stroma had a significantly shorter cancer specific survival
compared to the rest (15-year probability of event-free survival
(P-EFS) was 6765% and 3469% in the two groups) (Figure 4 A).
Interestingly, high expression of PDGFRb in the stroma of
adjacent normal prostate tissue was also associated with a
significantly reduced survival in patients managed by watchful
waiting (15-year P-EFS was 6865% and 4169% in the two
groups) (Figure 4 B).
High tumor and non-malignant stroma PDGFRb immuno-
staining was associated with an increased relative risk for prostate
cancer specific death in a univariate Cox regression analysis
(Table 2). In multivariate Cox regression analysis including the
known prognostic marker GS and local tumour stage, high stromal
PDGFRb in tumor and non-malignant tissue was not an
independent prognostic marker (data not shown).
Discussion
The present analyses uncovered a set of novel associations
between the tumor stroma PDGFRb status and histopathological
characteristics, including positive correlations with Gleason score,
tumor stage and tumor size (Table 1). These findings are
reminiscent of the recently described situation in breast cancer
where stromal PDGFRb expression was positively correlated with
high grade [21]. These findings raise the question of the
underlying mechanism(s). As of now it is not possible to conclude
whether the associations are caused by an epithelial-induced
stromal phenotype or by a stroma-induced epithelial phenotype.
The analyses of the present study also revealed significant
associations between clinical characteristics, including survival,
and the stromal PDGFRb expression in the non-malignant present
tissue (Table 1). This observation of prognostically significant
properties of the non-malignant tissue adds to a series of similar
observations that together have led to proposing the term ‘‘tumor
indicating non-malignant tissue’’ (TINT), which implies that
analyses of non-malignant prostate tissue can yield prognostic
information [2,10]. Other recent studies have presented similar
findings following analyses of e.g. pAKT, pEGFR and AR
[2,10,22]. From a practical perspective this is important since
many diagnostic biopsies only sample non-malignant tissue.
The underlying biology of the variations in stromal PDGFRb
expression should be better clarified. From the present analyses it
Figure 3. Stromal PDGFRb expression is correlated with
Gleason grade. PDGFRb staining in tumor stroma was more common
in cases with Gleason score 8–10 tumors as compared with patients
with a Gleason score 4–6 or Gleason score 7 (A). Presence of PDGFRb
immunostaining was more common in the normal prostate tissue
stroma when a Gleason score 8–10 tumor was present in the prostate
compared to if the tumor had Gleason score 4–6 (B).
doi:10.1371/journal.pone.0010747.g003
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secondary to the presence of near-by malignant tissue as suggested
in animal models [8], or if it rather reflects a tumor-permissive
environment which causally contributes to formation of more
malignant tumors.
The analyses including double staining with aSMA and
PDGFRb antibodies revealed that the PDGFRb expression
occurred in aSMA -positive cells (Figure 2). However, it was also
noted that these cells, in tumors scored as having a PDGFRb-
positive stroma, occurred together with aSMA -positive/
PDGFRb-negative cells. These findings thus clearly exemplify
the molecular heterogeneity among the cells of the non-malignant
fibromusclar stroma and of the fibroblast-like tumor stroma.
Similar findings have been made in experimental tumors [23]. As
also suggested by others [24], the findings should stimulate to an
improved classification of these subsets and continued analyses of
their functional significance.
The associations between high stromal PDGFRb expression
and shorter survival indicate that this receptor is causally linked to
the clinical course of the disease and thus also suggests targeting of
PDGF receptors for therapeutic purposes. Some smaller studies
have been reported where imatinib have been used in prostate
cancer without any obvious effects [25,26]. The findings from the
present study, demonstrating large variations in stromal PDGFRb
expression, suggest that future studies evaluating this approach will
require more stringent procedures for patient selection. In this
context it can also be noted that epithelial PDGFRb expression
was only rarely detected in this study (data not shown).
Furthermore, no associations between this expression and clinical
or histopathological characteristics were observed.
A series of topics for future studies are suggested by the present
findings. Experimental studies involving co-cultures of epithelial
and stromal cells should help to clarify if the stroma-epithelial
associations have their predominant mechanistic basis in the
stromal or epithelial compartment. Another interesting topic for
future studies would be to investigate to what extent the stromal
and epithelial phenotypes are linked to individual prostate cancer
risk genes. Finally, continued analyses are required to understand
if the tumor-associated variations in the non-malignant tissue are a
cause or a consequence of the tumor formation. Careful tissue
analyses in prospective studies might be required to clarify this
issue.
Materials and Methods
Patients and tissue microarray
Tissue specimens were collected from patients who underwent
transurethral resection of the prostate (TURP) at the hospital in
Va ¨stera ˚s, Sweden, between 1975 and 1991. Histological analysis
showed presence of prostate cancer. Median age at TURP was 74
years (range 51–95 years). Information concerning absence or
presence of benign prostate hyperplasia was not available. Tissue
specimens were formalin-fixed and paraffin-embedded followed by
regrading according to the Gleason system. The specimens were
used to construct a tissue micro array (TMA) using a Beecher
Instrument (Sun Prairie, WI, USA). The TMA:s contained 5–8
samples of tumor tissue representing both the primary and
secondary Gleason grade and 4 samples of non-malignant tissue
from each patient. The patients had not received any anti-cancer
Table 2. Cox regression for stromal PDGFRb in tumor and
non-malignant tissue of patients followed with watchful
waiting.
Variable N RR P-value 95% CI
Univariate analysis
Tumor stromal
PDGFRb**
,1.0 178 1*
$1.0 66 2.4 ,0.001 1.5–4.0
Non-malignant
stromal PDGFRb**
,0.5 205 1*
$0.5 74 2.3 0.002 1.4–3.8
*Reference value.
**Cox regression analysis using stromal PDGFRb as categorical variables.
Abbreviations: RR, relative risk; CI, confidence interval.
doi:10.1371/journal.pone.0010747.t002
Figure 4. PDGFRb expression in the stroma of tumors and non-malignant prostate tissue surrounding tumors predicts cancer
specific survival. Patients divided into two groups depending on stromal expression of PDGFRb in tumor (A) and non-malignant prostate tissue
surrounding tumors (B). Solid line, high PDGFRb in tumor stroma ($1.0); dashed line, low PDGFRb in tumor stroma (,1.0; A). Solid line, high PDGFRb
in non-malignant stroma ($0.5); dashed line, low PDGFRb in non-malignant stroma (,0.5; B).
doi:10.1371/journal.pone.0010747.g004
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shortly following diagnosis for detection of metastases. There were
377 patients included in the study, of which 293 patients were
followed with watchful waiting after TURP. At symptoms from
metastases patients received palliative treatment with androgen
ablation and in a few cases radiation therapy or oestrogen therapy,
according to therapy traditions in Sweden during that time. Also,
84 patients that were treated with palliative treatment immediately
after diagnosis were analyzed. The median overall survival for the
patient group followed with watchful waiting was 5.6 years.
Ninety-two of the TURP specimens were graded as Gleason score
(GS) 4–5, 107 patients as GS 6, 63 patients had GS 7, and 115
patients GS 8–10. 3 patients (4.1%) with GS 6, 4 patients (8.2%)
with GS 7, and 33 patients (33.7%) with GS 8–10 had bone
metastases at diagnosis. In August 2003, 36 patients (9.5%) were
still alive, 131 patients (34.7%) had died from prostate cancer and
210 patients (55.7%) had died from other causes. The material was
collected according to Swedish regulations at a time when
informed consent was not required. The research ethical
committee at Umea ˚ university hospital (Regional Ethical Review
Board in Umea ˚) approved of the study and waived the need for
consent.
In this material we have already analyzed factors of potential
prognostic significance such as Gleason score, tumor volume,
tumour stage, tumor cell proliferation and vascular density and the
data obtained were now related to the current PDGFRb findings
[2,27].
PDGFRb immunohistochemistry
PDGFRb immunohistochemistry was performed as described in
Nupponen et al 2008 [28]. Anti- PDGFRb (rabbit monoclonal,
#3169, Cell Signaling Technology, Danvers, MA, USA) was used
at a concentration of 2 mg/ml. The staining intensity was scored
separately in stroma and around vessels as negative (0), weak (1),
moderate (2) or strong (3). The PDGFRb staining score are the
median values of five to eight scored samples of tumor tissue or
four scored samples of nonmalignant tissue. For correlation
analysis the samples were scored as positive for PDGFRb if
staining was detected in at least one of the TMA cores.
Immunofluorescence
Immunofluorescent stainings of the TMAs was performed as
above (in the immunohistochemistry section) until the incubation
with the anti- PDGFRb antibody. Sections were then washed in
PBS with 0.1% Tween-20 (PBT) 365 min. This was followed by a
1 h incubation with the second primary antibody, mouse
monoclonal aSMA (M0851, clone 1A4, Dako Cytomation,
Glostrup, Denmark) diluted 1:100 in 20% goat serum in PBT.
After washing in PBT for 365 min, slides were incubated with
biotinylated goat anti-mouse antibody (E0432, Dako Cytomations
1:500) for 45 min at RT. This was followed by another 365 min
washing in PBT. The slides were then incubated with Alexa-Flour
488 goat anti-rabbit secondary antibody (A11008, Invitrogen,
Carlsbad, CA, USA) diluted 1:100 in PBT for 45 min at RT.
Following washing; the slides were incubated for 45 min with Cy3-
Streptavidin conjugate (Sigma-Aldrich) diluted 1:500 in PBT for
45 min at RT. After washing the slides were dried and mounted
with Vectashield mounting medium with DAPI (Vector Labora-
tories, Burlingame, CA, USA).
Statistics
Bivariate correlations were calculated with the Pearson’s
correlation test. Correlations between categorical variables and
continuous variables were analyzed using the Spearman’s rank
correlation test. Data was collected at the time of prostate cancer
diagnosis.
Patients included in survival analyses with the Kaplan-Meier
and Cox regression were followed with watchful waiting. The
duration of event-free survival (EFS) is defined as the time from
TURP until the date of prostate cancer death, death of other
cause, or until the date of last follow-up. Event in the survival
analysis was defined as prostate cancer death, thereby showing
cancer-specific survival. Differences in outcome were tested with
the log-rank test. The prognostic significance of PDGFRb
immunoreactivity was evaluated with Cox regression analysis
alone and combined with GS and local tumour stage. Probability
of event-free survival (P-EFS) is presented6standard error (SE).
The level of statistical significance was defined as P ,0.05 (two-
sided). Statistical analysis was performed using the SPSS 17.0.0
software for OS X (SPSS Inc., Chicago, IL, USA).
Supporting Information
Figure S1 PDGFRb expression occasionally varies within the
prostate tissue of the same patient. Heterogenous PDGFRb
staining patterns was observed in many tumors. A and B illustrate
different parts of the same prostate cancer. Scale bar=200 mM.
Found at: doi:10.1371/journal.pone.0010747.s001 (7.24 MB EPS)
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